Compare Diageo plc (DEO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs State Street SPDR S&P Biotech ETF — how do they compare? Diageo plc trades at $82.33 (market cap $45.41B), while State Street SPDR S&P Biotech ETF trades at $156.19. The key difference: Diageo plc pays a 4.02% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Diageo plc nearer its low. Which is the better fit depends on your goals.
| DEO | XBI | |
|---|---|---|
Market Cap | $45.41B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $115.33 | $164.28 |
52-Week Low | $72.47 | $85.16 |
Enterprise Value | $66.23B | — |
Dividend Yield | 4.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $82.50, up 0.57% today, with a bullish technical trend and strong profitability metrics including a 12.19% net margin and 22.29% ROE. Recent earnings show mixed results with a Q4 2025 beat but a Q2 2025 miss, while analyst sentiment is positive with 49% buy ratings. The stock faces headwinds from weak U.S. spirits demand and promotional pressures, as noted in recent Deutsche Bank and UBS reports from July 2026.
The outlook hinges on management's strategy reset in August 2026 to address U.S. volume declines and margin pressures. Investment appeal lies in its discounted valuation relative to historical multiples and dividend yield, but risks include sustained consumer moderation trends and execution challenges in key markets.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
